Bausch + Lomb (NYSE:BLCO) Price Target Raised to $21.00

Bausch + Lomb (NYSE:BLCO) had its price target hoisted by HC Wainwright from $20.00 to $21.00 in a research note published on Monday, MarketBeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Bausch + Lomb’s Q3 2026 earnings at $0.17 EPS, Q4 2026 earnings at $0.28 EPS, FY2026 earnings at $0.68 EPS, Q1 2027 earnings at $0.12 EPS, Q2 2027 earnings at $0.25 EPS, Q3 2027 earnings at $0.21 EPS, Q4 2027 earnings at $0.31 EPS and FY2027 earnings at $0.89 EPS.

Other analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft set a $16.00 price target on shares of Bausch + Lomb in a research note on Thursday, April 30th. Wall Street Zen upgraded shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. UBS Group assumed coverage on shares of Bausch + Lomb in a research report on Thursday, July 30th. They issued a “buy” rating and a $21.00 target price for the company. Citigroup lifted their target price on shares of Bausch + Lomb from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Finally, Evercore set a $17.00 target price on shares of Bausch + Lomb in a research note on Monday, July 6th. Five equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Bausch + Lomb currently has an average rating of “Hold” and an average target price of $18.75.

Bausch + Lomb Price Performance

BLCO opened at $16.73 on Monday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.02 and a current ratio of 1.55. The stock has a market capitalization of $5.98 billion, a P/E ratio of -34.86, a P/E/G ratio of 0.54 and a beta of 0.56. The company’s 50-day simple moving average is $15.98 and its two-hundred day simple moving average is $16.41. Bausch + Lomb has a 52-week low of $13.53 and a 52-week high of $18.92.

Hedge Funds Weigh In On Bausch + Lomb

Institutional investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Bausch + Lomb by 729.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after purchasing an additional 2,042 shares during the period. Caitong International Asset Management Co. Ltd grew its position in Bausch + Lomb by 104.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after buying an additional 1,136 shares during the period. Royal Bank of Canada grew its position in Bausch + Lomb by 67.1% during the first quarter. Royal Bank of Canada now owns 3,657 shares of the company’s stock valued at $58,000 after buying an additional 1,468 shares during the period. Wells Fargo & Company MN increased its holdings in Bausch + Lomb by 31.2% during the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after buying an additional 1,403 shares during the last quarter. Finally, Focus Partners Wealth purchased a new stake in Bausch + Lomb during the third quarter valued at approximately $170,000. Institutional investors own 11.07% of the company’s stock.

Bausch + Lomb News Roundup

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $21 price target for Bausch + Lomb (BLCO), signaling confidence in the company’s longer-term value. HC Wainwright Forecasts Strong Price Appreciation for Bausch + Lomb Stock
• Positive Sentiment: The analyst raised projected EPS for the first and second quarters of 2027 to $0.12 and $0.25, respectively, from $0.07 and $0.22. These increases suggest some improvement is expected in parts of the 2027 earnings outlook.
• Neutral Sentiment: HC Wainwright’s updated 2027 quarterly estimates are $0.12 for Q1, $0.25 for Q2, $0.21 for Q3 and $0.31 for Q4, resulting in a full-year forecast of $0.89 per share.
• Negative Sentiment: The firm cut its Q3 2026 EPS estimate to $0.17 from $0.21 and its Q4 estimate to $0.28 from $0.34. Its FY2026 forecast fell to $0.68 from $0.83, below the broader consensus estimate of approximately $0.81.
• Negative Sentiment: Longer-term revisions were also mixed to negative: Q3 2027 EPS was reduced to $0.21 from $0.23, Q4 2027 to $0.31 from $0.41, and FY2027 to $0.89 from $0.93. The reductions point to weaker expected profitability than previously modeled.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.